MarvelBiome, Inc.
Woburn, MA · Founded 2019 · CIK 0001815665 · Biotech · Private
Microbe-based biopharmaceuticals (engineered microbial therapeutics)
marvelbiome.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $55M
- 4 Form D · Oct 2025
- 11 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 35
- 4 granted · 31 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,258,952 | |
| Private capital raised | Form D · SEC | $3,100,001 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $39,561,794 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2285 | Dicerna Pharmaceuticals, Inc. | — | $90M |
| 2286 | CytoDyn Inc. | — | $88M |
| 2287 | Geneoscopy, Inc. | — | $58M |
| 2288 | MarvelBiome, Inc. | — | $55M |
| 2289 | Voyager Therapeutics | — | $119M |
| 2290 | Precision Fermentation, Inc. | — | $53M |
| 2291 | Xencor | — | $46M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Mukesh ChatterDirector
- Priti ChatterDirector
- J. GovindanDirector · Executive Officer
- Jothi GovindanDirector · Executive Officer
- G. GundDirector
- Elamparithi JayamaniExecutive Officer
- Gary RuvkunDirector
- Rudolph TanziDirector
Patents
- Methods And Uses Of Microbiome Compositions, Components, Or Metabolites For Treating Insulin-associated Diseasesapplication
- Methods And Uses Of Microbiome Compositionsgranted
- Microbial Compositions Comprising Ellagitannin And Methods Of Useapplication
- Methods And Uses Of Microbiome Compositionsapplication
- Methods And Uses Of Microbiome Compositions, Components, Or Metabolites For Treating Neurodegenerative Diseasesapplication
- Methods And Uses Of Microbiome Compositions, Components, Or Metabolites For Treating Neurodegenerative Diseasesgranted
- Methods And Uses Of Microbiome Compositions, Components, Or Metabolites For Treating Eye Disordersapplication
- Methods And Uses Of Microbiome Compositions, Components, Or Metabolites For Treating Vagus Nerve Associated Diseases, Disorders, And Conditionsapplication
- Compositions And Methods For Extending Lifespanapplication
- Compositions And Methods For Characterizing A Microbiomeapplication
- Compositions And Methods For Characterizing A Microbiomegranted
- Microbial Compositions Comprising Ellagitannin And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.